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1. Introduction
Irritable bowel syndrome (IBS) is a common functional 
gastrointestinal disorder (FGID), affecting between 10% 
and 20% of the population globally [1]. The condition is 
characterized by a combination of symptoms including 
abdominal pain, bloating, distention, flatulence, and 
disturbed bowel habits seen as constipation (IBS-C), 
diarrhea (IBS-D), or a combination of both (IBS-
mixed) [2]. Currently, the Rome IV Diagnostic Criteria, 
providing symptom-based criteria for diagnosis, is 
applied for the diagnosis of IBS and its subtypes [2]. 
Besides the gastrointestinal (GI) symptoms, most patients 
suffering from IBS also experience a broad spectrum of 
extraintestinal symptoms, such as fatigue, fibromyalgia, 
poor social functioning, and reduced emotional well-
being. Thus, although not being a fatal and organic disease, 
IBS is shown to have severe impact on quality of life [3,4]. 
The etiology of IBS is not fully understood, but it is 
evident that the condition involves a dysfunction in the 
gut microbiota, seen as a dysbiosis leading to altered 
composition and diversity of the microbes in the gut 
[5]. The increased risk of developing IBS that has been 
observed after an infectious enteritis and/or excessive use 
of antibiotics supports the assumption of a dysbiotic gut as a 
contributor to the onset of IBS symptoms [6,7]. In addition 
to altered gut microbiota, alterations in one or more of the 
control systems that contributes to the regulation of bowel 
function, including the central nervous system, the enteric 
nervous system, the enteroendocrine system, and the 
enteric immune system is presumed to be involved in the 
generation of IBS [8,9]. Suggested mechanisms includes 
alterations in the gut-brain axis, low-grade inflammation, 
visceral hypersensitivity, abnormalities in the GI endocrine 
cells, changes in the GI motility, postinfectious changes, 
bacterial overgrowth, malabsorption of carbohydrates, 
abnormalities in serotonin metabolism, gene interactions, 
and alterations in the gut microbiota composition 
[3,5,6,10,11]. An overview of suggested mechanisms 
and factors involved in the pathophysiology of IBS is 
summarized in Figure 1. 
As the gut microbiota composition and activity is 
decisive for several pathways suggested to be involved in 
IBS, different therapeutic approaches aim to target and 
manipulate a potentially dysbiotic gut. The current review 
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is an attempt to summarize the most recent developments 
in treatment options targeting the gut microbiota and point 
out future perspectives for novel treatment approaches in 
IBS related to disturbed gut microbiota.
2. Microbiota and IBS
2.1. The human gut microbiota 
The human gut is inhabited by huge amounts of 
microorganisms important for maintaining GI 
homeostasis, including bacteria, virus, fungi, archae, and 
eukaryotes. More than 2000 different bacterial species have 
been identified in the human gut, of whom the majority 
belongs to the four main phyla Bacteroidetes, Firmicutes, 
Actinobacteria, and Proteobacteri [12]. While the gut 
microbiota is the present community of microorganisms, 
the gut microbiome refers to the entire set of genomic 
elements decisive for the microbiota in the gut. A healthy 
composition of the gut microbiome is essential for a broad 
range of physiological functions, as the gut microbial 
genes are decisive for the bacterial richness in the gut 
and hence the function of the gut microbiota [13]. In 
healthy subjects, the composition of the gut microbiota 
is determined by both genetic and environmental factors, 
of which the genetic factors are suggested to explain only 
5–10% of the bacterial variability among individuals [14]. 
The environmental factors decisive for the gut microbiota 
composition include diet, geographical location, 
surgery, smoking, depression, frequency of treatment 
with antibiotics and use of certain nonantibiotic drugs, 
among others [15]. Microbial richness, seen as bacterial 
diversity, is usually considered an indicator of good health. 
In contrast, reduced bacterial diversity and imbalance 
of the gut microbiota, referred to as dysbiosis, has been 
associated with impaired metabolism and a broad range of 
different diseases [16].
2.2. Implications of the gut microbiota in IBS
It is suggested in the literature that the gut microbiota 
profile of IBS patients differs from the gut microbiota 
Postinfectious
Figure 1. An overview of suggested mechanisms and factors involved in irritable bowel syndrome (IBS).
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profile of healthy controls [17–20]. In addition, several 
differences in gut microbiota composition among IBS 
subtypes have been detected [21]. Methane-producing 
bacteria, such as Methanobacterialles, have been reported 
to be more abundant in IBS-C and less abundant in IBS-D 
compared to healthy subjects, whereas butyrate-producing 
bacteria, such as Erysipelotrichaceae and  Ruminococcaceae, 
are found in lower concentration in IBS patients than in 
healthy subjects [22]. Although the findings are overall 
inconsistent regarding gut microbiota composition and 
diversity in IBS, data in general suggest that there is a 
relative abundance of proinflammatory bacterial species 
such as Enterobacteriaceae, and decreased presence 
of Lactobacilli and Bifidobacteri [20]. In addition, an 
increase in Firmicutes to Bacteroidetes ratio, and increased 
Streptococci and Ruminococcus species are observed when 
IBS patients are compared to healthy subjects [23–26]. 
IBS patients are most often characterized by a 
reduction in bacterial diversity, referred to as dysbiosis, 
when compared to healthy subjects [19]. Of note, it is 
suggested that IBS patients who do not respond to dietary 
interventions suffer from a severe dysbiosis [15]. However, 
although it is well documented that IBS patients have 
alterations in the gut microbiota composition and can be 
characterized by a dysbiotic gut, the specific microbial 
signature characterizing these patients is still unknown 
[5].
3. Current therapeutic options targeting gut microbiota 
in IBS 
A multidisciplinary approach is the recommended 
treatment option in IBS [2]. A better understanding 
of the disease, combined with life-style interventions 
including diet, exercise, and breathing techniques, is 
proven to be effective for reducing symptom severity in 
IBS patients [3]. In addition, psychological and behavioral 
treatment and hypnotherapy has also been shown to 
reduce IBS symptoms and improve quality of life [27]. 
Nonpharmacological treatment options are preferably the 
first-choice in IBS, as available drugs are most likely to 
target only the predominant symptom. Due to the broad 
diversity of symptoms experienced by most IBS patients, 
drug treatment is often perceived as inadequate and do not 
lead to total control of symptoms [2]. Hence, the need of 
novel and more personalized treatment approaches in IBS 
is of great need. 
3.1. Dietary strategies modulating gut microbiota in IBS 
Diet composition and food intake have been shown to play 
an important role in the symptom generation in IBS patients, 
and most of them claim that their symptoms can be related 
to the consumption of different foods [28]. In recent years, 
the interaction between diet, gut microbiota composition, 
and severity of IBS symptoms has gained a lot of attention 
and emerged as an important pathophysiological basis for 
the treatment [29]. Lately, the “brain-gut” axis is referred to 
as the “brain-gut-microbiota” axis [30]. Diet contributes in 
the pathogenesis of IBS by modulating the gut microbiome 
and the normal gut microenvironment [31]. The food we 
eat and its breakdown products are capable of altering the 
gut microbiota composition and the colonic fermentation, 
in addition to interacting with the gut immune system 
and affecting the gut permeability, motility, and visceral 
sensation [32]. 
3.1.1. Basic dietary advices in IBS 
Several modifications in the diet are shown to enhance 
symptom severity in IBS. The first line dietary treatment 
for IBS patients is to follow the dietary guidelines from 
the modified National Institute for Health and Care 
Excellence (NICE) diet, as recommended by the British 
Dietetic Association [33]. The NICE-diet highlights the 
importance of regular meals and recommends reducing 
the intake of carbonated drinks, chewing gum, fatty and 
spicy foods, coffee, alcohol, onion, cabbage, and beans as 
well as supplementing the diet with fibers such as psyllium 
husk. 
3.1.2. Dietary fiber modifications
Dietary fibers can be divided into soluble and insoluble 
fibers, according to their chemical and physiological 
properties. Soluble fibers can further be divided into 
viscous (gel-forming) and nonviscous fibers [34]. The 
dietary fibers include nondigestible short-chain and 
long-chain carbohydrates and lignin, a complex polymer 
percent in plants [35]. Overall, including fibers in the diet 
has several beneficial health effects, such as improving 
stool consistency, lowering blood cholesterol levels, 
and improving glycemic control [36].  For a long time, 
it was believed that IBS was caused by a deficient intake 
of fibers; hence, it was widely recommended that IBS 
patients increased their intake [37]. However, the effects 
of different fibers have proven to be of importance, as 
soluble fibers are shown to improve IBS symptoms while 
insoluble fibers, on the other hand, are shown to exacerbate 
symptoms [38,39]. Supplementation with soluble and 
moderately fermentable fibers such as psyllium and oats 
is a recommended treatment in IBS, shown to improve 
symptom severity and beneficially modulate stool 
consistency in all IBS-subtypes [36]. Several randomized 
controlled trials (RCTs) investigating the effect of fiber 
supplementation on microbiota composition in healthy 
subjects have suggested that supplementation with fructo-
oligosaccharides (FOS) and galacto-oligosaccharides 
(GOS), known for their prebiotic activity, increases 
the abundance of Bifidobacterium, an oligosaccharide 
fermenting bacteria suggested to be beneficial for human 
health [40]. 
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A broad range of studies have investigated the effect of 
supplementation with different types of fibers in patients 
with IBS, and increasing amount of evidence indicates that 
the dietary fibers acting as prebiotics, such as inulin and 
oligosaccharides, are able to influence the composition of 
the gut microbiota [41–43]. Fermentation of dietary fibers 
by colonic bacteria leads to the production of short-chain 
fatty acids (SCFAs), and concentrations of fecal SCFAs 
have been investigated as a marker of fecal fermentation 
reflecting the gut microbiota activity in IBS patients [44]. 
Distinct alterations in fecal SCFA concentrations have been 
reported between IBS patients and healthy controls, and 
propionate and butyrate in particular have been suggested 
as possible biomarkers for the distinction between IBS and 
healthy individuals [45]. 
3.1.3. The low-FODMAP diet
If basic dietary modifications do not improve 
symptoms, a diet with a restricted intake of fermentable 
oligosaccharides, disaccharides, monosaccharides, and 
polyols (FODMAPs) is proven by several metaanalyses to 
significantly reduce symptom severity in IBS, especially 
abdominal pain and bloating [46,47]. FODMAPs are short-
chained carbohydrates that are poorly absorbed in the 
small intestines, and when fermented by colonic bacteria, 
production of gas and osmotic action causes symptoms 
such as bloating and diarrhea [47]. Notably, a diet with a 
restricted intake of FODMAPs is associated with distinct 
alterations in both function and composition of the gut 
microbiota, as well as modulations in fecal fermentation 
and production of SCFAs [44,48]. 
In a recent publication, we reported on the effect of a 
low-FODMAP diet combined with supplementation with 
FOS or placebo, in 20 patients with IBS-D or IBS-M [42]. 
We found the low-FODMAP diet to overall consistently 
improve symptom severity, and significantly more 
patients reported symptom relief when supplemented 
with placebo (maltodextrin) for 10 days, compared to the 
FOS supplementation (80% vs. 30%). The serum levels 
of proinflammatory interleukins (IL-6 and IL-8), total 
concentrations of SCFAs and n-butyric acid, as well as 
levels of bacteria in feces (Actinobacteria, Bifidobacterium, 
and Faecalibacterium prausnitzii), significantly decreased 
in response to the low-FODMAP diet. Ten days of 
supplementation with FOS increased the levels of these 
bacteria, whereas the levels of inflammatory markers 
and concentrations of SCFAs did not change [42]. 
Accordingly, the long-term health effect of adherence to 
the low-FODMAP diet as a dietary intervention is not 
established. The health effects of the changes observed in 
the gut microbiota composition and fecal fermentation 
in response to a diet with low content of fermentable 
carbohydrates is currently unknown [49]; thus, the long-
term use of a strict low-FODMAP diet can be questioned. 
Although FODMAPs can be experienced as symptom 
generators in IBS, most FODMAPs can be classified as 
prebiotics and serve as food for the gut microbiota [42]. 
A reduction of FODMAPs may in most cases correlate 
with a reduction both in dietary fibers and prebiotics, 
which in the long term might not be beneficial for the 
gut microbiota composition and activity. Hence, there is 
a need for establishing the long-term effect of a restricted 
FODMAP diet on the gut microbiota, as well as for 
continuing to highlight the importance of reintroducing 
all those well-tolerated FODMAPs in the diet as soon as 
possible.
3.2. Probiotic supplementation and gut microbiota in 
IBS
Probiotics are defined as “live microorganisms that, when 
administered in adequate amounts, confer a health benefit 
on the host” [50]. Probiotics normally contains gut-
friendly bacteria, and sometimes also yeast, and can be 
provided in the form of a dietary supplement or consumed 
as ingredients in fermented foods such as yoghurt, 
kombucha, and sauerkraut. Since an altered gut microbiota 
composition is suggested as a central contributor to the 
pathogenesis of IBS, supplementing the diet with probiotics 
is a well investigated treatment strategy in IBS, which aims 
to beneficially manipulate a dysbiotic gut [51]. Several 
metaanalyses of randomized controlled trials (RCTs) 
investigating the effects of probiotics compared to placebo 
in IBS patients have concluded that probiotic supplements 
significantly improve overall IBS symptoms and abdominal 
pain [52–55]. Of note, the use of monostrain or multistrain 
probiotics varies between studies, and it is suggested that 
supplements containing a multistrain probiotic (several 
different bacterial strains) might be more effective than 
monostrain supplements in improving symptoms. In a 
recent review article summarizing the most up-to-date 
research on the effects of probiotic supplementation on 
symptom severity in IBS patients, we reported that the 
effects of probiotic supplementation were more distinct 
with the use of a multistrain supplement [51]. In addition, 
we found the effect to be more distinct in the studies with 
an intervention period of 8 weeks or more, suggesting that 
probiotics supplemented over a period of time have the 
potential to improve IBS symptoms [51].
Overall, much remains to be answered as to which 
strains facilitate the most beneficial effects in IBS. Although 
probiotic supplements seem to have beneficial effects in 
improving IBS symptoms, their function and mechanistic 
effects are relatively unknown. Current literature has 
suggested that probiotics act through improvement of 
gut barrier function, inhibition of pathogenic bacteria 
overgrowth, and prevention of pathogenic invasion of 
the host, as well as production of signal substances such 
as SCFAs and neurotransmitters [56]. The fact that the 
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degree of dysbiosis and gut microbiota composition most 
likely varies greatly both between subtypes of IBS patients 
and between each subject leads to the question of whether 
it is possible to target these individual differences in 
future therapy. According to current literature, individual 
microbiota profiling may in the future enable personalized 
or customized probiotic therapy.
3.3. Antibiotics in IBS
Nonabsorbable antibiotics have been investigated in the 
treatment of IBS in several large-scale double-blinded 
and placebo controlled RCTs, and have been found 
to serve as an effective treatment option [5]. In 2015, 
rifaximin, a rifamycine derivate with a broad range 
of antibacterial effects against aerobic and anaerobic 
organisms in the GI tract, was approved by the US Food 
and Drug Administration for the treatment of adults with 
IBS-D [57]. Less than 0.5% of the oral dose of rifaximin 
is absorbed; hence, this antibiotic has low toxicity and 
no significant adverse effects and drug interactions [58]. 
Although the route of action of nonabsorbable antibiotics 
in IBS is unclear, relief of IBS symptoms is suggested to 
occur due to reduction in the total gut bacterial load and 
changes in the composition of the gut microbiota, as well 
as modulation of the intestinal permeability and the gut 
microbiome [20]. 
Three multicenter RCTs, named TARGET 1-3, have 
demonstrated a beneficial effect of rifaximin in improving 
IBS symptoms [59,60]. TARGET 1 and 2 included IBS 
patients without constipation. The primary outcome was 
proportion of patients with relief of global IBS symptoms, 
with adequate relief defined as self-reported symptom 
relief for at least 2 of the first 4 weeks after the intervention. 
Both interventions revealed that rifaximin given in doses 
of 550 mg 3 times a day for 2 weeks significantly reduced 
overall symptoms and bloating when compared to placebo 
(40.8% vs. 31.2% in TARGET 1 and 40.6% vs. 32.2% in 
TARGET 2) [59]. The TARGET 3 study included adult 
patients with only IBS-D, and those patients responding to 
a 2-week treatment with rifaximin as provided in TARGET 
1 and 2 but relapsed during an observation phase, were 
randomly assigned to an additional treatment with either 
rifaximin or placebo for another 2 weeks. The percentage 
of responders were significantly greater with rifaximin 
group with placebo (38.1% vs. 31.5%), and the rates of 
adverse events were low [60]. This study demonstrates 
that repeated treatments with rifaximin are well tolerated 
and can be considered effective in reducing symptom in 
patients suffering from diarrhea predominant IBS.
Although rifaximin is not indicated in IBS-C, a small 
double-blind trial has suggested that rifaximin may 
improve symptoms also in patients with constipation [61]. 
The study showed that rifaximin given in combination with 
neomycin significantly reduced the degree of constipation 
and bloating, compared to neomycin given with placebo. 
The constipation severity scores were significantly lower in 
the neomycin and rifaximin group (28.6 ± 30.8) compared 
to neomycin alone (61.2 ± 24.1) [61].
4. Future perspectives and potential treatments 
manipulating the gut microbiota in IBS 
4.1. Fecal microbiota transplantation in IBS
Fecal microbiota transplantation (FMT) has recently 
gained a lot of attention due to the strong evidence for 
the role of dysbiosis in the IBS pathogenesis. FMT is an 
approach involving application of a solution of fecal 
material from a healthy donor into the gut of a receiver, 
aiming to restore a dysfunctional microbial composition 
into a healthy homeostasis and hence improve the function 
of the gut microbiota [5]. A Japanese open-label study 
in 10 IBS patients reported in 2017 that FMT treatment 
improved both the psychological status and stool form. In 
addition, the authors suggest that a donor holding a high 
fecal concentration of Bifidobacterium might be a positive 
predictor for successful FMT [62]. A systematic review by 
Halkjær et al. reported in 2017 that 28 out of 48 patients 
(58%) experienced a beneficial outcome of FMT treatment, 
and importantly, no adverse events were reported [63]. 
The review included only a restricted number of FMT 
studies, as the data from RCTs then were limited. In the 
last two years, several RCTs evaluating the effect of FMT in 
IBS have been published, reporting somehow conflicting 
results regarding alleviation of IBS symptoms. 
Three recent Norwegian studies, all using FMT 
administered through gastroscopy or colonoscopy, have 
reported beneficial effects. Johnsen et al. assessed the effect 
of FMT in a parallel-group RCT, with 60 patients assigned 
to FMT treatment and 30 assigned to placebo [64]. The 
trial included IBS patients with moderate-to-severe IBS-D 
or IBS-M, and the primary outcome was reduction in total 
IBS severity scoring system (IBS-SSS) of more than 75 
points. Fifty-five patients assigned to FMT treatment and 
28 assigned to placebo completed the trial. They reported 
that the FMT treatment significantly reduced symptoms 
compared to placebo, with a 65% response in the FMT 
group and a 43% response in the placebo group [64]. 
Results from our study, including 13 IBS patients and 
13 healthy donors receiving FMT, support the findings 
of Johnsen et al. [65,66]. According to symptom scores, 
the symptoms were significantly improved following 
FMT [65]. When analyzing fecal samples, we found 
that the donors and the IBS patients had significantly 
different bacterial strains signals for Ruminococcus 
gnavus, Actinobacteria, and Bifidobacteria, in addition to 
significantly differences between several gut microbiota 
taxa and concentrations of SCFAs at baseline, which of note 
became nonsignificant 3 weeks following FMT [66]. At 
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20/28 weeks after FMT, the changes in the gut microbiota 
were similar between IBS patients and donors; thus, the 
patient’s microbiota profile became more or less similar 
to those of the donors. Those IBS patients responding to 
FMT had different gut microbiota profile and SCFA profile 
than the nonresponders, and significant correlations were 
reported between the gut microenvironment and IBS 
symptoms [66].
El-Salhy et al. recently performed a placebo-controlled 
RCT, evaluating the effect of two different doses of FMT 
[67]. This study, including 165 IBS patients allocated to 
either placebo 30 g or 60 g FMT, demonstrated that FMT 
was effective in reducing IBS symptoms and fatigue, as 
well as increasing the quality of life. The primary outcome 
was a positive response defined as a reduction of 50 points 
or more in the total IBS-SSS score. Response occurred in 
23.6% of the patients in the placebo group, 76.9% in the 30 
g FMT group, and 89.1% in the 60 g FMT group, suggesting 
that the response to FMT increases according to dose. In 
addition, a significant change in gut bacterial profile was 
observed in the groups receiving FMT [67]. Following, an 
open-label study including the 10 patients not responding 
to the 30 g FMT treatment was conducted [68]. The ten 
patients received a 60 g FMT transplant, of which 7 (70%) 
responded to treatment with significant improvements in 
IBS-symptoms, degree of fatigue, and quality of life. These 
results further highlight that increasing doses and/or 
repeated FMT increases the response [68]. 
Results conflicting with those of the Norwegian studies 
were presented by a Danish trial by Halkjær et al. [69]. 
This randomized, double-blind, and placebo-controlled 
trial included 52 patients with moderate-to-severe IBS, 
randomized to capsules with FMT or placebo for 12 days, 
with 6 months of follow up. Here, a significant reduction 
of symptoms according to the IBS-SSS core was observed 
for placebo, but not for the FMT treatment. The patients 
receiving the FMT capsules had an increase in the 
fecal microbiota diversity that was not observed in the 
placebo group; however, the authors state that altered gut 
microbiota is not enough to obtain clinical improvement 
in IBS [69]. Accordingly, although several studies 
investigating FMT as a treatment option in IBS obtain 
promising results regarding symptom severity and gut 
microbiota manipulation, the results are still conflicting. 
The outcome of FMT seems to be dependent on the donor; 
hence, a so-called “superdonor” seems to be essential for 
FMT to be an effective treatment [14]. 
Currently, FMT is only investigated in a research setting, 
and the available data on potential effects are too limited to 
draw sufficient conclusions. More RCTs investigating the 
long-term effects of FMT and its route of administration 
need to be carried out in order to potentially be able to 
offer FMT as a standardized treatment approach for IBS in 
a clinical setting. 
4.2. Targeting the gut microbiota in IBS
As our understanding of the implications of the gut 
microbiota in IBS is constantly evolving, the potential of 
treatments manipulating both the gut microbiome and 
the gut microbiota aiming to improve GI symptoms and 
severity of IBS is widening. Hopefully, determining the 
Figure 2. Suggested future therapies for irritable bowel syndrome (IBS), enabled by 
mapping of the individual gut microbiota profile and use of personalized and targeted 
treatment strategies.
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exact microbiota profile and degree of dysbiosis in each 
IBS patient will soon be an available tool for personalized 
treatment options, such as customized probiotic or FMT 
treatments and/or targeted use of antibiotics. An overview 
of some suggested future therapeutic strategies in IBS is 
shown in Figure 2. 
5. Conclusions
There is strong growing evidence suggesting that dysbiosis 
is central in the pathophysiology of IBS. Manipulation of 
the gut microbiota in order to improve IBS symptoms has 
evolved in the last decade as a novel treatment strategy 
and several different approaches have been investigated 
in order to improve the gut microbiota composition 
and hence improve symptoms. Dietary modifications 
including supplementation with fibers and probiotics are 
shown to improve symptoms and gut microbiota in IBS, 
although the exact probiotic mixture beneficial for each 
individual remains to be identified. The use of antibiotics 
still needs confirmation, although promising results have 
been reported with the use of rifaximin. Several studies 
investigating FMT obtain promising results regarding 
symptoms and gut microbiota manipulation in IBS; 
however, more data including long-term effects of FMT are 
required before it can be used as a customized treatment 
in the clinic.
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